Gonadotrophin-releasing hormone agonist treatment for sexual offenders: A systematic review

Abstract

Background:

Sexual offending is a significant international issue causing long-term consequences for victims, perpetrators and society.

Aims:

The purpose of this study was to review the existing research data assessing the efficacy of gonadotrophin-releasing hormone agonists for treating adult, male, sexual offenders.

Method:

The method of this review involved the examination of studies involving participants prescribed at least one month of a gonadotrophin-releasing hormone agonist for the purposes of reducing sexual drive related to offending. The primary outcome measures were recidivism rates and sexual functioning. Secondary outcome measures included assessment of side effects and effects on interpersonal/psychiatric functioning. Studies in the English language that were dated 1969–2015 were included.

Results:

Twelve eligible studies (323 participants) were identified. A reduction in a variety of measures of sexual functioning and/or risk was found in all studies. Robust recidivism data was limited. Medication was rarely described as ineffectual. All studies reported side effects. Reduction in bone density and potential long-term reduction in fertility in some subjects were issues of concern.

Conclusion:

Whilst identified studies showed promising results with respect to sexual functioning, challenges in performing randomised control trials in this subject group meant that included studies were methodologically limited. This review recommends that future research must be performed before the effectiveness and tolerability of gonadotrophin-releasing hormone agonists in this population can be confirmed.

Keywords

Sexual offenders hormonal treatments gonadotrophin-releasing hormone agonists

Get full access to this article

View all access options for this article.

References

Armijo-Olivo

Stiles

Hagen

et al . (2010) Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Projects Quality Assessment Tool: Methodological research. J Eval Clin Pract 18: 12–18.

Assumpcao

Garcia

et al . (2014) Pharmacologic treatment of paraphilias. Psychiatr Clin N Am 37: 173–181.

Bancroft

Tennent

Loucas

et al . (1974) The control of deviant sexual behavior by drugs. I. Behavioural changes following oestrogens and antiandrogens. Br J Psychiatry 125: 310–315.

Baumgartner

Scalora

Huss

(2002) Assessment of Wilson Sex Fantasy Questionnaire among child molesters and nonsexual forensic offenders. Sex Abuse 18: 303–316.

Belchetz

Plant

Nakai

et al . (1978) Hypophyseal responses to continuous and intermittent delivery of hypothalamic gonadotrophin releasing hormone. Science 202: 631–633.

Bradford

JMW

(2001) The neurobiology, neuropharmacology and pharmacological treatment of the paraphilias and compulsive sexual behaviour. Can J Psychiatry 46: 26–34.

Briken

Hill

Berner

(2003) Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: A systematic review. J Clin Psychiatry 64: 890–897.

Briken

Nika

Berner

(2001) Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. J Sex Marital Ther 27(1): 45–55.

Czerny

Briken Berner

(2002) Antihormonal treatment of paraphilic patients in German forensic psychiatric clinics. Eur Psychiatry 17(2): 104–106.

10.

Dennis

Khan

Ferriter

(2012) Psychological interventions for adults who have sexually offended or are at risk of reoffending. Cochrane Database Syst Rev 12: CD007507. Available at: http://www.thecochranelibrary.com (accessed April 2015).

11.

Garcia

Delavenne

Assumpcao

AFA

et al . (2013) Pharmacological treatment of sex offenders with paraphilic disorder. Curr Psychiatry Rep 15: 356.

12.

Giltay

Gooren

(2009) Potential side effects of androgen deprivation treatment in sex offenders. J Am Acad Psychiatry Law 37(1): 53–58.

13.

Grubin

(2008) The use of medication in the treatment of sex offenders. Prison Service Journal 137: 37–43.

14.

Guay

DRP

(2009) Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther 31(1): 1–31.

15.

Hansen

Lykke-Olesen

(1997) Treatment of dangerous sexual offenders in Denmark. J Forensic Psychiatry 8: 195–199.

16.

Kottalgi

Ross

et al . (2012) Treatment with triptorelin in mentally disordered sex offenders: Experience from a maximum-security hospital. Letter to the editor. J Clin Psychopharmacol 32(5): 739–740.

17.

Jackson

Waters

(2005) Criteria for the systematic review of health promotion and public health interventions. Health Promot Int 20(4): 367–374.

18.

Jordan

Fromberger

Stolpmann

et al . (2011) The role of testosterone in sexuality and paraphilia–a neurobiological approach. Part II: Testosterone and paraphilia. J Sex Med 8(11): 3008–3029.

19.

Khan

Ferriter

Huband

et al . (2015) Pharmacological interventions for those who have offended or are at risk of offending (Review). Cochrane Database Syst Rev 2: CD007989. Available at: http://www.thecochranelibrary.com (accessed April 2015).

20.

Koo

Ahn

Hong

et al . (2014) Effects of chemical castration on sex offenders in relation to the kinetics of serum testosterone recovery: Implications for dosing schedule. J Sex Med 11: 1316–1324.

21.

Krueger

Kaplan

(2001) Depot-leuprolide acetate for treatment of paraphilias: A report of twelve cases. Arch Sex Behav 30(4): 409–422.

22.

Kruger

Menkveld

Stander

et al . (1986) Sperm morphologic features as a prognostic factor in in vitro fertilization. Fertil Steril 46: 1118–1123.

23.

Loosen

Purdon

Pavlou

(1994) Effects on behaviour of gonadal function in men with gonadotrophin-releasing hormone antagonists. Am J Psychiatry 151: 271–273.

24.

Lucy Faithfull Foundation (2013) Eradicating Child Sexual Abuse (ECSA), Project Templates. Available at: http://www.lucyfaithfull.org.uk/files/ECSA_project_core_sotp.pdf (accessed 13 Jan 2017).

25.

Marques

Day

Nelson

et al . (1994) Effects of cognitive-behavioural treatment on sex offender recidivism. Crim Just Behav 21: 28–54.

26.

McEvoy

(1999) AHFS drug information. Bethesda, MD: American Society of Health System Pharmacists.

27.

Mchichi

Kadri

(2004) Moroccan women with a history of child sexual abuse and its long-term repercussions: a population-based epidemiological study. Arch Womens Ment Health 7(4): 237–242.

28.

Ministry of Justice (2013) Gender differences in substance misuse and mental health amongst prisoners. Results from the Surveying Prisoner Crime Reduction (SPCR) longitudinal cohort study of prisoners. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/220060/gender-substance-misuse-mental-health-prisoners.pdf (accessed 7 April 2017).

29.

Moher

Liberati

Tetzlaff

et al . (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 62: 1006–1012.

30.

Molnar

Buka

Kessler

(2001) Child sexual abuse and subsequent psychopathology: Results from the National Comorbidity Survey. Am J Public Health 91(5): 753–760.

31.

National Society for the Prevention of Cruelty to Children (2014a) Estimating the costs of child sexual abuse in the UK. Available at: http://www.nspcc.org.uk/globalassets/documents/research-reports/estimating-costs-child-sexual-abuse-uk.pdf (accessed 25 March 2015)

32.

National Society for the Prevention of Cruelty to Children (2014b) How safe are our children? Available at: http://www.nspcc.org.uk/globalassets/documents/research-reports/how-safe-children-2014-report.pdf (accessed 4 April 2015).

33.

Office for National Statistics (2014) Crime in England and Wales, Year Ending September 2014. Available at: http://www.ons.gov.uk/ons/dcp171778_392380.pdf (accessed 25 March 2015).

34.

Post

Mezey

Maxwell

et al . (2002) The rape tax tangible and intangible costs of sexual violence. J Interpers Violence 17(7): 773–782.

35.

Rosen

Riley

Wagner

et al . (1997) The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 49: 822–830.

36.

Rösler

Witztum

(1998) Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. New Engl J Med 338: 416–422.

37.

Safarinejad (2009) Treatment of nonparaphilic hypersexuality in men with a long-acting analog of gonadotropin-releasing hormone. J Sex Med 6: 1151–1164.

38.

Saleh

Niel

Fishman

(2004) Treatment of paraphilia in young adults with leuprolide acetate: A preliminary case report series. J Forensic Sci 49(6):1343–1348.

39.

Schober

Kuhn

Kovacs

et al . (2005) Leuprolide acetate suppresses pedophilic urges and arousability. Arch Sex Behav 34(6): 691–705.

40.

Schot

LPC

Schuurs

AHWM

(1990) Pathophysiology of bone loss in castrated animals. J Steroid Biochem Mol Biol 37(3): 461–465.

41.

Sexual Offences, Crime and Misconduct Research Unit (SOCAMRU) (2016) Evaluation of the use of Medication to Manage Sexual Arousal (MMSA) with individuals convicted of a sexual offence who are experiencing high levels of sexual preoccupation: Report to the National Offender Management Service, NHS and HMP Whatton. Unpublished.

42.

Thibaut

(2012) Pharmacological Treatmnet of Paraphilias. Isr J Psychaitry Relat Sci 49: 4.

43.

Thibaut

Cordier

Kuhn

(1996) Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: A lifetime treatment? Psychoneuroendocrinology 21(4): 411–419.

44.

Thibaut

De La Barra

Gordon

et al . (2010) WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the biological treatment of paraphilias. World J Biol Psychiatry 11: 604–655.

45.

Thibaut

Kuhn

Cordier

et al . (1998) Hormonal treatment of sex offenses. Encephale XXIV: 132–137.

46.

Turner

Basdeekis-Jozsa

Briken

(2013) Prescription of testosterone-lowering medications for sex offender treatment in German forensic-psychiatric institutions. J Sex Med 10: 570–578.

47.

Volavka

Citrome

(1999) Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res 35: S23–S33.

48.

World Health Organization (WHO) (1992) Laboratory Manual for the Examination of Human Semen Cervical Mucus Interaction. 3rd ed. Cambridge: Cambridge University Press.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.60 MB

0.14 MB